They will also carry out of the aims of Project 2. In Aim 1 of the application, we will define the role of wildtype SS18 in synovial sarcoma proliferation. In Aim 2 of the application, we will identify the factors controlling SS18 stability and incorporation into the BAF complex. The aims will allow us to define the molecular pathways required for wildtype SS18 protein stability, and to delineate how modulation of these factors can be employed for the development of targeted therapeutics for the treatment of synovial sarcoma both in children and adults.
|Effective start/end date||7/1/20 → 6/30/21|
- Dana-Farber Cancer Institute (1205703//1U54CA231638-01 REV)
- National Cancer Institute (1205703//1U54CA231638-01 REV)